| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vaccines, DNA | 42 | 2024 | 98 | 10.340 |
Why?
|
| AIDS Vaccines | 25 | 2024 | 70 | 6.600 |
Why?
|
| HIV Envelope Protein gp120 | 21 | 2024 | 133 | 5.110 |
Why?
|
| HIV Antibodies | 23 | 2024 | 144 | 5.030 |
Why?
|
| HIV-1 | 21 | 2024 | 715 | 2.940 |
Why?
|
| Antibodies, Neutralizing | 15 | 2024 | 206 | 2.570 |
Why?
|
| Antibodies, Viral | 11 | 2014 | 318 | 2.280 |
Why?
|
| Viral Vaccines | 6 | 2020 | 49 | 1.900 |
Why?
|
| HIV Infections | 14 | 2024 | 961 | 1.900 |
Why?
|
| Immunization, Secondary | 12 | 2024 | 44 | 1.850 |
Why?
|
| Adjuvants, Immunologic | 6 | 2014 | 227 | 1.390 |
Why?
|
| Plague | 5 | 2011 | 23 | 1.260 |
Why?
|
| Neutralization Tests | 19 | 2018 | 122 | 1.260 |
Why?
|
| Immunization | 9 | 2014 | 133 | 1.250 |
Why?
|
| Influenza Vaccines | 4 | 2013 | 97 | 1.240 |
Why?
|
| Vaccination | 7 | 2018 | 353 | 1.180 |
Why?
|
| Rabbits | 15 | 2017 | 332 | 1.150 |
Why?
|
| Influenza, Human | 4 | 2014 | 206 | 1.100 |
Why?
|
| CD4 Antigens | 3 | 2024 | 149 | 1.080 |
Why?
|
| Virus Diseases | 3 | 2014 | 118 | 1.050 |
Why?
|
| Animals | 47 | 2021 | 20530 | 1.040 |
Why?
|
| env Gene Products, Human Immunodeficiency Virus | 4 | 2018 | 55 | 0.990 |
Why?
|
| Vaccines, Subunit | 9 | 2017 | 40 | 0.980 |
Why?
|
| T-Lymphocytes | 8 | 2015 | 1004 | 0.970 |
Why?
|
| Mice, Inbred BALB C | 15 | 2014 | 892 | 0.950 |
Why?
|
| Antigens, Bacterial | 5 | 2016 | 207 | 0.930 |
Why?
|
| Epitopes | 5 | 2020 | 295 | 0.900 |
Why?
|
| Yersinia pestis | 6 | 2014 | 33 | 0.860 |
Why?
|
| Plague Vaccine | 3 | 2010 | 5 | 0.860 |
Why?
|
| Vaccines | 2 | 2017 | 95 | 0.800 |
Why?
|
| Antibody-Producing Cells | 1 | 2021 | 12 | 0.760 |
Why?
|
| Antibody Formation | 4 | 2017 | 112 | 0.760 |
Why?
|
| Technology, Pharmaceutical | 2 | 2014 | 20 | 0.760 |
Why?
|
| Hemagglutinins, Viral | 2 | 2014 | 12 | 0.750 |
Why?
|
| Antibodies, Monoclonal | 6 | 2024 | 866 | 0.740 |
Why?
|
| Immunoglobulin G | 13 | 2020 | 462 | 0.740 |
Why?
|
| Cytokines | 4 | 2014 | 933 | 0.730 |
Why?
|
| Codon | 3 | 2006 | 53 | 0.720 |
Why?
|
| Immunity, Cellular | 5 | 2011 | 175 | 0.710 |
Why?
|
| Cytomegalovirus Vaccines | 2 | 2013 | 5 | 0.700 |
Why?
|
| Cytomegalovirus | 4 | 2013 | 91 | 0.680 |
Why?
|
| DNA | 3 | 2018 | 840 | 0.670 |
Why?
|
| Hemagglutinin Glycoproteins, Influenza Virus | 2 | 2013 | 41 | 0.670 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 4 | 2014 | 88 | 0.670 |
Why?
|
| Mice | 25 | 2021 | 10768 | 0.660 |
Why?
|
| Polysaccharides | 2 | 2020 | 142 | 0.660 |
Why?
|
| Immunity, Innate | 2 | 2015 | 794 | 0.620 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 9 | 2013 | 453 | 0.610 |
Why?
|
| Science | 1 | 2019 | 34 | 0.600 |
Why?
|
| B-Lymphocytes | 3 | 2018 | 568 | 0.580 |
Why?
|
| Betacoronavirus | 1 | 2020 | 177 | 0.570 |
Why?
|
| Humans | 49 | 2024 | 62455 | 0.570 |
Why?
|
| Immunoglobulin Variable Region | 1 | 2017 | 34 | 0.570 |
Why?
|
| Racism | 1 | 2019 | 87 | 0.550 |
Why?
|
| Viral Envelope Proteins | 3 | 2007 | 102 | 0.530 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 202 | 0.530 |
Why?
|
| Vaccinia virus | 2 | 2007 | 71 | 0.530 |
Why?
|
| Immunologic Factors | 1 | 2017 | 104 | 0.530 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 216 | 0.530 |
Why?
|
| Myeloid Differentiation Factor 88 | 2 | 2014 | 204 | 0.520 |
Why?
|
| Biotechnology | 2 | 2014 | 44 | 0.510 |
Why?
|
| Interferon Regulatory Factor-7 | 1 | 2015 | 33 | 0.500 |
Why?
|
| HIV Antigens | 5 | 2010 | 18 | 0.490 |
Why?
|
| Saponins | 3 | 2014 | 29 | 0.480 |
Why?
|
| Pore Forming Cytotoxic Proteins | 3 | 2011 | 34 | 0.480 |
Why?
|
| Nucleotidyltransferases | 1 | 2015 | 61 | 0.470 |
Why?
|
| Phospholipids | 1 | 2014 | 81 | 0.430 |
Why?
|
| DNA-Binding Proteins | 3 | 2014 | 1176 | 0.420 |
Why?
|
| Respiratory Tract Infections | 1 | 2014 | 89 | 0.420 |
Why?
|
| Viruses | 1 | 2014 | 79 | 0.420 |
Why?
|
| Female | 27 | 2024 | 32375 | 0.410 |
Why?
|
| Protein Engineering | 3 | 2010 | 82 | 0.410 |
Why?
|
| Antigens, Viral | 3 | 2008 | 134 | 0.400 |
Why?
|
| Cholesterol | 1 | 2014 | 259 | 0.400 |
Why?
|
| Vaccines, Attenuated | 2 | 2013 | 36 | 0.390 |
Why?
|
| Pneumonia, Bacterial | 1 | 2013 | 89 | 0.380 |
Why?
|
| Influenza A Virus, H5N1 Subtype | 1 | 2011 | 12 | 0.380 |
Why?
|
| Interferon-gamma | 7 | 2013 | 567 | 0.380 |
Why?
|
| C-Reactive Protein | 1 | 2012 | 166 | 0.370 |
Why?
|
| Gene Transfer Techniques | 2 | 2004 | 314 | 0.360 |
Why?
|
| HIV | 1 | 2011 | 70 | 0.360 |
Why?
|
| Cancer Vaccines | 2 | 2009 | 47 | 0.360 |
Why?
|
| Bacterial Infections | 1 | 2012 | 148 | 0.350 |
Why?
|
| Inflammasomes | 1 | 2014 | 332 | 0.350 |
Why?
|
| Antibody Affinity | 1 | 2010 | 19 | 0.340 |
Why?
|
| Bacterial Vaccines | 1 | 2011 | 87 | 0.330 |
Why?
|
| Biological Warfare | 1 | 2009 | 3 | 0.330 |
Why?
|
| Membrane Proteins | 1 | 2015 | 889 | 0.320 |
Why?
|
| Electroporation | 2 | 2013 | 34 | 0.320 |
Why?
|
| Viral Tropism | 3 | 2018 | 51 | 0.320 |
Why?
|
| Cross Reactions | 4 | 2016 | 131 | 0.310 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2011 | 671 | 0.310 |
Why?
|
| HEK293 Cells | 2 | 2021 | 614 | 0.300 |
Why?
|
| Severe Acute Respiratory Syndrome | 2 | 2005 | 24 | 0.300 |
Why?
|
| Mice, Inbred C57BL | 5 | 2017 | 3384 | 0.290 |
Why?
|
| Plasmids | 5 | 2008 | 291 | 0.290 |
Why?
|
| Smallpox | 1 | 2007 | 9 | 0.290 |
Why?
|
| Immunity, Mucosal | 1 | 2008 | 52 | 0.280 |
Why?
|
| Smallpox Vaccine | 1 | 2007 | 14 | 0.280 |
Why?
|
| Enzyme-Linked Immunospot Assay | 3 | 2018 | 12 | 0.260 |
Why?
|
| Prions | 1 | 2006 | 24 | 0.260 |
Why?
|
| Vaccinia | 1 | 2006 | 32 | 0.260 |
Why?
|
| Transfection | 3 | 2013 | 688 | 0.260 |
Why?
|
| Virus Replication | 3 | 2013 | 318 | 0.260 |
Why?
|
| DNA, Viral | 2 | 2011 | 231 | 0.260 |
Why?
|
| Glycosylation | 3 | 2020 | 138 | 0.250 |
Why?
|
| Gene Products, env | 1 | 2005 | 17 | 0.250 |
Why?
|
| DNA, Recombinant | 1 | 2005 | 46 | 0.240 |
Why?
|
| Influenza A virus | 1 | 2006 | 123 | 0.240 |
Why?
|
| Membrane Glycoproteins | 2 | 2005 | 669 | 0.230 |
Why?
|
| Cell Line | 7 | 2018 | 2033 | 0.230 |
Why?
|
| Receptors, Complement 3d | 1 | 2004 | 16 | 0.220 |
Why?
|
| Injections, Jet | 1 | 2004 | 1 | 0.220 |
Why?
|
| Complementarity Determining Regions | 1 | 2024 | 38 | 0.220 |
Why?
|
| Microinjections | 1 | 2004 | 68 | 0.220 |
Why?
|
| Microspheres | 1 | 2004 | 56 | 0.220 |
Why?
|
| Immunization Schedule | 2 | 2017 | 17 | 0.210 |
Why?
|
| Vaccines, Synthetic | 3 | 2008 | 71 | 0.210 |
Why?
|
| China | 2 | 2019 | 168 | 0.210 |
Why?
|
| Promoter Regions, Genetic | 1 | 2005 | 669 | 0.200 |
Why?
|
| Cryoelectron Microscopy | 1 | 2024 | 202 | 0.190 |
Why?
|
| Mice, Knockout | 4 | 2015 | 2093 | 0.190 |
Why?
|
| ROC Curve | 2 | 2013 | 277 | 0.190 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2020 | 641 | 0.190 |
Why?
|
| Skin | 2 | 2008 | 377 | 0.190 |
Why?
|
| Hemagglutination Inhibition Tests | 2 | 2014 | 8 | 0.190 |
Why?
|
| Adolescent | 5 | 2024 | 6145 | 0.190 |
Why?
|
| Binding Sites | 1 | 2024 | 898 | 0.190 |
Why?
|
| Gold | 1 | 2004 | 226 | 0.180 |
Why?
|
| Sumoylation | 1 | 2021 | 17 | 0.180 |
Why?
|
| Adult | 9 | 2024 | 16564 | 0.180 |
Why?
|
| Cricetulus | 2 | 2020 | 100 | 0.180 |
Why?
|
| Cytomegalovirus Infections | 2 | 2012 | 66 | 0.180 |
Why?
|
| CHO Cells | 2 | 2020 | 190 | 0.180 |
Why?
|
| Recombinant Proteins | 3 | 2020 | 698 | 0.180 |
Why?
|
| Male | 11 | 2024 | 29366 | 0.180 |
Why?
|
| Vero Cells | 3 | 2005 | 80 | 0.180 |
Why?
|
| Neoplasms | 2 | 2009 | 1344 | 0.180 |
Why?
|
| RNA, Small Interfering | 4 | 2021 | 893 | 0.170 |
Why?
|
| Human Experimentation | 3 | 2008 | 32 | 0.160 |
Why?
|
| Disease Outbreaks | 1 | 2020 | 113 | 0.160 |
Why?
|
| Macrophages | 2 | 2018 | 1039 | 0.160 |
Why?
|
| Protein Domains | 1 | 2020 | 148 | 0.160 |
Why?
|
| Drug Design | 1 | 2020 | 136 | 0.160 |
Why?
|
| Antibody Specificity | 2 | 2010 | 103 | 0.150 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2017 | 287 | 0.150 |
Why?
|
| Nuclear Proteins | 2 | 2021 | 770 | 0.150 |
Why?
|
| Hepatitis B Antibodies | 1 | 2018 | 9 | 0.150 |
Why?
|
| Hepatitis B Vaccines | 1 | 2018 | 14 | 0.150 |
Why?
|
| Hepatitis B virus | 1 | 2018 | 15 | 0.150 |
Why?
|
| Hepatitis B | 1 | 2018 | 32 | 0.140 |
Why?
|
| Antibodies, Bacterial | 2 | 2010 | 194 | 0.140 |
Why?
|
| Recombinant Fusion Proteins | 3 | 2010 | 494 | 0.140 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 2 | 2008 | 26 | 0.140 |
Why?
|
| Receptors, CCR5 | 1 | 2018 | 59 | 0.140 |
Why?
|
| Cells, Cultured | 2 | 2015 | 2148 | 0.140 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2017 | 97 | 0.140 |
Why?
|
| Biomarkers | 2 | 2013 | 1379 | 0.140 |
Why?
|
| Prospective Studies | 3 | 2014 | 3246 | 0.140 |
Why?
|
| Vaccines, Inactivated | 2 | 2008 | 13 | 0.130 |
Why?
|
| Gene Expression Regulation, Viral | 2 | 2013 | 47 | 0.130 |
Why?
|
| Receptors, Fc | 1 | 2016 | 24 | 0.130 |
Why?
|
| Middle Aged | 6 | 2024 | 17293 | 0.130 |
Why?
|
| Caenorhabditis elegans Proteins | 1 | 2021 | 425 | 0.130 |
Why?
|
| Interferon Regulatory Factor-3 | 1 | 2015 | 97 | 0.120 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 2 | 2016 | 26 | 0.120 |
Why?
|
| Body Weight | 2 | 2007 | 377 | 0.120 |
Why?
|
| Immediate-Early Proteins | 2 | 2012 | 45 | 0.120 |
Why?
|
| Blotting, Western | 2 | 2008 | 609 | 0.120 |
Why?
|
| Interleukin-18 | 1 | 2014 | 73 | 0.110 |
Why?
|
| Interferon-beta | 1 | 2014 | 80 | 0.110 |
Why?
|
| Interferon-alpha | 1 | 2014 | 102 | 0.110 |
Why?
|
| Administration, Intravenous | 1 | 2014 | 66 | 0.110 |
Why?
|
| Genetic Fitness | 1 | 2014 | 34 | 0.110 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 2014 | 34 | 0.110 |
Why?
|
| Lipid A | 1 | 2014 | 66 | 0.110 |
Why?
|
| Caenorhabditis elegans | 1 | 2021 | 675 | 0.110 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2014 | 15 | 0.110 |
Why?
|
| Spike Glycoprotein, Coronavirus | 2 | 2005 | 111 | 0.110 |
Why?
|
| Gene Expression | 3 | 2018 | 834 | 0.110 |
Why?
|
| Biolistics | 1 | 2013 | 4 | 0.110 |
Why?
|
| Diarrhea | 1 | 2014 | 76 | 0.110 |
Why?
|
| Drug Combinations | 1 | 2014 | 151 | 0.110 |
Why?
|
| Injections | 1 | 2013 | 81 | 0.110 |
Why?
|
| Feedback, Physiological | 1 | 2013 | 60 | 0.110 |
Why?
|
| Signal Transduction | 3 | 2015 | 3016 | 0.100 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2012 | 198 | 0.100 |
Why?
|
| gag Gene Products, Human Immunodeficiency Virus | 1 | 2013 | 38 | 0.100 |
Why?
|
| Interleukin-1beta | 1 | 2014 | 261 | 0.100 |
Why?
|
| Trans-Activators | 2 | 2012 | 309 | 0.100 |
Why?
|
| Communicable Diseases | 1 | 2014 | 88 | 0.100 |
Why?
|
| Gene Expression Regulation, Bacterial | 1 | 2014 | 164 | 0.100 |
Why?
|
| Receptors, HIV | 1 | 2012 | 15 | 0.100 |
Why?
|
| Virus Attachment | 1 | 2012 | 18 | 0.100 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2014 | 344 | 0.100 |
Why?
|
| Statistics, Nonparametric | 1 | 2013 | 212 | 0.100 |
Why?
|
| DNA Damage | 2 | 2012 | 284 | 0.100 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2012 | 76 | 0.100 |
Why?
|
| DNA-Directed DNA Polymerase | 1 | 2012 | 15 | 0.100 |
Why?
|
| RNA Interference | 2 | 2013 | 611 | 0.100 |
Why?
|
| Host-Pathogen Interactions | 1 | 2014 | 261 | 0.100 |
Why?
|
| Trauma Centers | 1 | 2012 | 118 | 0.090 |
Why?
|
| Genetic Vectors | 2 | 2010 | 844 | 0.090 |
Why?
|
| E2F1 Transcription Factor | 1 | 2011 | 16 | 0.090 |
Why?
|
| Analysis of Variance | 1 | 2012 | 608 | 0.090 |
Why?
|
| Lethal Dose 50 | 1 | 2011 | 15 | 0.090 |
Why?
|
| Virology | 1 | 2010 | 15 | 0.090 |
Why?
|
| Genetics, Microbial | 1 | 2010 | 11 | 0.090 |
Why?
|
| Brain | 2 | 2011 | 1546 | 0.080 |
Why?
|
| United States | 2 | 2024 | 7696 | 0.080 |
Why?
|
| Lymph Nodes | 1 | 2011 | 222 | 0.080 |
Why?
|
| Diagnosis, Differential | 1 | 2013 | 959 | 0.080 |
Why?
|
| Viral Proteins | 1 | 2012 | 259 | 0.080 |
Why?
|
| HIV Core Protein p24 | 1 | 2009 | 17 | 0.080 |
Why?
|
| Trisaccharides | 1 | 2009 | 9 | 0.080 |
Why?
|
| Interleukin-5 | 1 | 2009 | 36 | 0.080 |
Why?
|
| Dimerization | 2 | 2007 | 145 | 0.080 |
Why?
|
| Disease Progression | 1 | 2014 | 1159 | 0.080 |
Why?
|
| Virulence Factors | 1 | 2010 | 85 | 0.080 |
Why?
|
| Sensitivity and Specificity | 1 | 2012 | 1138 | 0.080 |
Why?
|
| Predictive Value of Tests | 1 | 2012 | 1076 | 0.080 |
Why?
|
| Mutation | 2 | 2014 | 2576 | 0.080 |
Why?
|
| Young Adult | 2 | 2024 | 4607 | 0.080 |
Why?
|
| Immunity | 1 | 2009 | 107 | 0.080 |
Why?
|
| Cell Cycle Proteins | 1 | 2011 | 394 | 0.080 |
Why?
|
| Iridovirus | 1 | 2008 | 4 | 0.070 |
Why?
|
| Orthomyxoviridae | 1 | 2008 | 26 | 0.070 |
Why?
|
| Anti-Bacterial Agents | 1 | 2014 | 783 | 0.070 |
Why?
|
| Plasminogen Activators | 1 | 2008 | 10 | 0.070 |
Why?
|
| Variola virus | 1 | 2007 | 1 | 0.070 |
Why?
|
| Research | 1 | 2009 | 192 | 0.070 |
Why?
|
| Severity of Illness Index | 1 | 2013 | 1537 | 0.070 |
Why?
|
| Chemoprevention | 1 | 2007 | 40 | 0.070 |
Why?
|
| Antigens | 1 | 2008 | 147 | 0.070 |
Why?
|
| Antibodies | 1 | 2008 | 182 | 0.070 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2007 | 363 | 0.070 |
Why?
|
| Vaccines, Combined | 1 | 2006 | 9 | 0.070 |
Why?
|
| Models, Animal | 1 | 2007 | 235 | 0.070 |
Why?
|
| Prion Diseases | 1 | 2006 | 10 | 0.070 |
Why?
|
| Aged | 2 | 2013 | 14203 | 0.070 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2007 | 222 | 0.070 |
Why?
|
| Emergency Service, Hospital | 1 | 2014 | 1064 | 0.060 |
Why?
|
| Golgi Apparatus | 1 | 2006 | 64 | 0.060 |
Why?
|
| Complement System Proteins | 1 | 2007 | 115 | 0.060 |
Why?
|
| Research Design | 1 | 2009 | 572 | 0.060 |
Why?
|
| Escherichia coli | 2 | 2007 | 708 | 0.060 |
Why?
|
| Antigen-Presenting Cells | 1 | 2006 | 178 | 0.060 |
Why?
|
| Feasibility Studies | 1 | 2007 | 561 | 0.060 |
Why?
|
| Cytopathogenic Effect, Viral | 1 | 2005 | 11 | 0.060 |
Why?
|
| Epitope Mapping | 1 | 2005 | 50 | 0.060 |
Why?
|
| Cytoplasm | 1 | 2006 | 277 | 0.060 |
Why?
|
| Kidney | 1 | 2007 | 444 | 0.060 |
Why?
|
| Survival Analysis | 1 | 2006 | 575 | 0.060 |
Why?
|
| Clinical Trials as Topic | 1 | 2008 | 452 | 0.060 |
Why?
|
| Protein Structure, Tertiary | 1 | 2006 | 667 | 0.060 |
Why?
|
| Colony Count, Microbial | 1 | 2004 | 60 | 0.060 |
Why?
|
| Drug Delivery Systems | 1 | 2008 | 324 | 0.060 |
Why?
|
| Immunogenicity, Vaccine | 1 | 2024 | 15 | 0.060 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2004 | 35 | 0.060 |
Why?
|
| Amino Acid Sequence | 1 | 2007 | 1592 | 0.060 |
Why?
|
| Models, Molecular | 1 | 2008 | 1142 | 0.060 |
Why?
|
| Molecular Sequence Data | 1 | 2007 | 1988 | 0.060 |
Why?
|
| Administration, Cutaneous | 1 | 2004 | 31 | 0.050 |
Why?
|
| DNA Primers | 1 | 2004 | 292 | 0.050 |
Why?
|
| Guinea Pigs | 1 | 2004 | 84 | 0.050 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2004 | 126 | 0.050 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2004 | 542 | 0.050 |
Why?
|
| Species Specificity | 1 | 2004 | 334 | 0.050 |
Why?
|
| Aged, 80 and over | 1 | 2013 | 5390 | 0.050 |
Why?
|
| Macaca mulatta | 1 | 2004 | 248 | 0.050 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 2 | 2013 | 42 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2006 | 712 | 0.050 |
Why?
|
| Immunoblotting | 2 | 2013 | 202 | 0.050 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2013 | 233 | 0.050 |
Why?
|
| Double-Blind Method | 1 | 2024 | 738 | 0.050 |
Why?
|
| Bacterial Proteins | 1 | 2008 | 769 | 0.050 |
Why?
|
| Meiosis | 1 | 2021 | 64 | 0.040 |
Why?
|
| Ovum | 1 | 2021 | 63 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2005 | 1634 | 0.040 |
Why?
|
| Argonaute Proteins | 1 | 2021 | 132 | 0.040 |
Why?
|
| Rats | 1 | 2004 | 1976 | 0.040 |
Why?
|
| RNA, Messenger | 1 | 2005 | 1520 | 0.040 |
Why?
|
| Disease Models, Animal | 1 | 2006 | 2165 | 0.040 |
Why?
|
| Protein Multimerization | 1 | 2018 | 174 | 0.030 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2018 | 179 | 0.030 |
Why?
|
| Volunteers | 1 | 2016 | 17 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2018 | 669 | 0.030 |
Why?
|
| Peptide Fragments | 1 | 2018 | 411 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2021 | 1339 | 0.030 |
Why?
|
| Phosphoenolpyruvate Sugar Phosphotransferase System | 1 | 2014 | 2 | 0.030 |
Why?
|
| Aluminum Hydroxide | 1 | 2014 | 3 | 0.030 |
Why?
|
| Thiazoles | 1 | 2014 | 47 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2018 | 983 | 0.030 |
Why?
|
| Mutagenesis, Insertional | 1 | 2014 | 90 | 0.030 |
Why?
|
| Gene Library | 1 | 2014 | 102 | 0.030 |
Why?
|
| Genes, Immediate-Early | 1 | 2013 | 7 | 0.030 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 2013 | 30 | 0.030 |
Why?
|
| Phenols | 1 | 2014 | 77 | 0.030 |
Why?
|
| Protein Binding | 1 | 2018 | 1595 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2014 | 365 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 206 | 0.030 |
Why?
|
| Genotype | 1 | 2014 | 649 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2014 | 768 | 0.020 |
Why?
|
| Promyelocytic Leukemia Protein | 1 | 2012 | 15 | 0.020 |
Why?
|
| Transduction, Genetic | 1 | 2013 | 235 | 0.020 |
Why?
|
| Immunologic Memory | 1 | 2014 | 290 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 928 | 0.020 |
Why?
|
| Protein Transport | 1 | 2013 | 405 | 0.020 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2011 | 27 | 0.020 |
Why?
|
| Caffeine | 1 | 2011 | 48 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2012 | 317 | 0.020 |
Why?
|
| Logistic Models | 1 | 2014 | 1272 | 0.020 |
Why?
|
| Galactosyltransferases | 1 | 2009 | 16 | 0.020 |
Why?
|
| Molecular Biology | 1 | 2010 | 67 | 0.020 |
Why?
|
| Immunity, Humoral | 1 | 2009 | 40 | 0.020 |
Why?
|
| DNA Repair | 1 | 2011 | 245 | 0.020 |
Why?
|
| Fibroblasts | 1 | 2011 | 392 | 0.020 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2009 | 33 | 0.020 |
Why?
|
| Hypersensitivity, Delayed | 1 | 2008 | 19 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2014 | 2530 | 0.020 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2009 | 138 | 0.020 |
Why?
|
| Vasculitis | 1 | 2008 | 50 | 0.020 |
Why?
|
| Histones | 1 | 2011 | 480 | 0.020 |
Why?
|
| Models, Biological | 1 | 2012 | 1177 | 0.020 |
Why?
|
| Virulence | 1 | 2007 | 195 | 0.020 |
Why?
|
| Antigen-Antibody Complex | 1 | 2006 | 52 | 0.020 |
Why?
|
| Receptors, IgG | 1 | 2006 | 37 | 0.020 |
Why?
|
| Interleukin-10 | 1 | 2007 | 159 | 0.020 |
Why?
|
| Cricetinae | 1 | 2006 | 368 | 0.020 |
Why?
|
| Risk Factors | 1 | 2014 | 5287 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2012 | 1500 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2007 | 1601 | 0.010 |
Why?
|